WILMINGTON, Mass., May 13 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.® (Nasdaq: DUSA), a dermatology company that is developing and marketing Levulan® Photodynamic Therapy (PDT) and other products focused on patients with common skin conditions, today announced that its Annual Meeting of Shareholders will be held on Thursday, July 29, 2010 at 11:00 AM at the Company's offices at 25 Upton Drive, Wilmington, MA. The Company also reported that it has nominated a slate of directors for election at the annual meeting, namely, Jay M. Haft, Esq., Chairman, Alfred Altomari, David M. Bartash, Alexander W. Casdin, Robert F. Doman, Paul Hondros, Magnus Moliteus and David M. Wurzer. The nomination of David M. Wurzer is being made as a result of the resolution of the Company's discussions with SRB Greenway Opportunity Fund, (QP), L.P. and SRB Greenway Opportunity Fund, L.P., and several affiliates ("SRB Funds"). A full copy of the agreement with the SRB Funds dated May 13, 2010 will be filed as an exhibit to the Company's Form 8-K being filed contemporaneously with this announcement.
"We are excited to propose such a strong slate of directors, which includes several new nominees. We believe their experience, successful track records and demonstrated corporate leadership will greatly benefit the Company and its shar